Schizophrenia Research
Volume 78, Issue 2 , Pages 157-159, 15 October 2005

Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients☆

  • Sonia Dollfus

      Affiliations

    • Department of psychiatry, Centre Esquirol, Centre Hospitalier et Universitaire, avenue de la Côte de Nacre, Caen, 14000, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 2 31 06 50 18; fax: +33 2 31 06 49 87.
    • ,
  • Véronique Olivier

      Affiliations

    • Lilly France, Neuroscience department, 13 rue Pagès, 92158 Suresnes Cedex, France
    • ,
  • Benoît Chabot

      Affiliations

    • Department of psychiatry, Centre Esquirol, Centre Hospitalier et Universitaire, avenue de la Côte de Nacre, Caen, 14000, France
    • ,
  • Cécile Déal

      Affiliations

    • Lilly France, Neuroscience department, 13 rue Pagès, 92158 Suresnes Cedex, France
    • ,
  • Elena Perrin

      Affiliations

    • Lilly France, Neuroscience department, 13 rue Pagès, 92158 Suresnes Cedex, France

Received 28 December 2004; received in revised form 31 May 2005; accepted 1 June 2005.

Abstract 

Objective

To compare the efficacy of two atypical antipsychotic drugs, olanzapine and risperidone, in schizophrenic patients with post-psychotic depression.

Results

A clinically significant decrease of MADRS scores occurred in patients treated with both drugs for 8 weeks.

Conclusion

Atypical antipsychotic drugs may be particularly appropriate when treating schizophrenic patients with depression.

Keywords: Schizophrenia, Post-psychotic depression, Atypical antipsychotics

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ This paper was presented at the 12th Association of European Psychiatry Congress, Geneva, April 15–18th, 2004.

PII: S0920-9964(05)00234-3

doi:10.1016/j.schres.2005.06.001

Schizophrenia Research
Volume 78, Issue 2 , Pages 157-159, 15 October 2005

Article Tools

* Image Usage & Resolution